Helius Medical Technologies Inc
NASDAQ:HSDT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Helius Medical Technologies Inc
NASDAQ:HSDT
|
US |
|
M
|
Moon Inc
OTC:MXXNF
|
HK |
|
Daodaoquan Grain and Oil Co Ltd
SZSE:002852
|
CN |
|
Camtek Ltd
F:CMZ
|
IL |
|
Link Bilgisayar Sistemleri Yazilimi ve Donanimi Sanayi ve Ticaret AS
IST:LINK.E
|
TR |
|
EnviTec Biogas AG
XETRA:ETG
|
DE |
|
Altius Renewable Royalties Corp
TSX:ARR
|
CA |
|
Leeku Industrial Co Ltd
KRX:025820
|
KR |
|
EROAD Ltd
NZX:ERD
|
NZ |
|
C
|
Clean Power Hydrogen PLC
LSE:CPH2
|
UK |
|
First Financial Northwest Inc
NASDAQ:FFNW
|
US |
|
ServiceNow Inc
NYSE:NOW
|
US |
|
Kangwon Land Inc
KRX:035250
|
KR |
|
MotorCycle Holdings Ltd
ASX:MTO
|
AU |
|
B
|
Bougainville Copper Ltd
ASX:BOC
|
PG |
Helius Medical Technologies Inc
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The company is headquartered in Newtown, Pennsylvania. The company went IPO on 2014-06-27. The firm focuses on developing, licensing or acquiring non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The firm's product, Portable Neuromodulation Stimulator (PoNS) is a class II, non-implantable medical device intended for use as a short-term treatment (14 weeks) of gait deficit due to symptoms from multiple sclerosis (MS), and balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with supervised therapeutic exercise (PoNS Treatment). The firm's subsidiaries include Helius Medical, Inc., Helius Medical Technologies (Canada), Inc., Helius NeuroRehab, Inc., Helius Canada Acquisition Ltd. and Heuro Canada, Inc.
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The company is headquartered in Newtown, Pennsylvania. The company went IPO on 2014-06-27. The firm focuses on developing, licensing or acquiring non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The firm's product, Portable Neuromodulation Stimulator (PoNS) is a class II, non-implantable medical device intended for use as a short-term treatment (14 weeks) of gait deficit due to symptoms from multiple sclerosis (MS), and balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with supervised therapeutic exercise (PoNS Treatment). The firm's subsidiaries include Helius Medical, Inc., Helius Medical Technologies (Canada), Inc., Helius NeuroRehab, Inc., Helius Canada Acquisition Ltd. and Heuro Canada, Inc.
Revenue: Fourth-quarter revenue was $5.2 million, driven mostly by $5.1 million of staking revenue, while full-year 2025 revenue was $6 million.
Staking: Management said Solana Company staked substantially all of its SOL and generated a 6.8% average net staking yield in Q4, above the 6.2% system-wide average.
Capital actions: The company raised over $29 million through its ATM when the stock traded above 1.0x mNAV and has since repurchased over $3 million of stock when the valuation fell below 1.0x mNAV.
Per-share growth: Management said SOL per share increased 14% over the 6 months since launching the digital asset treasury strategy.
New products: The company highlighted its Anchorage Digital and Kamino collaboration for borrowing against natively staked SOL and said it could add another 100 to 200 basis points of yield.
Strategy: Leaders described Solana Company as moving beyond a passive treasury into a broader platform focused on capital markets, asset management, and ecosystem partnerships, including Asia-Pacific infrastructure buildout.
